Results of Therapy Including Omalizumab in Adolescents With Recurrent Urticaria: Retrospective Cohort Study

Relevance. Omalizumab is recommended for treatment of severe forms of recurrent urticaria in children since 12 years old. Though the Omalizumab efficiency and safety in children with recurrent urticaria have not been studied specifically.Objective. To estimate results of the therapy including Omaliz...

Full description

Bibliographic Details
Published in:	Педиатрическая фармакология
Main Authors:	Vera G. Kalugina, Elena A. Vishneva, Leyla S. Namazova-Baranova, Polina R. Grinchik
Format:	Article
Language:	Russian
Published:	Union of pediatricians of Russia 2019-09-01
Subjects:	adolescent recurrent urticaria urticaria activity score second-generation antihistamines omalizumab efficiency safety
Online Access:	https://www.pedpharma.ru/jour/article/view/1739

Similar Items

Efficiency of Adding Omalizumab to Standard Therapy for Children with Recurrent Spontaneous Urticaria: Comparative Observational Study
by: Vera G. Kalugina, et al.
Published: (2020-08-01)

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga
by: Ana G. Lopes, et al.
Published: (2022-10-01)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
by: Elizabeth García-Gómez, et al.
Published: (2022-05-01)

Plasmapheresis: Is it a potential alternative treatment for chronic urticaria?
by: Aleksandraviciute Laima, et al.
Published: (2021-12-01)

Successful Treatment of Chronic Spontaneous Urticaria Associated with Autoimmune Thyroiditis: Clinical Case
by: Vera G. Kalugina, et al.
Published: (2019-12-01)

Modern Possibilities of Chronic Urticaria Therapy in Children
by: Leyla S. Namazova-Baranova, et al.
Published: (2018-07-01)

Omalizumab for the management of refractory chronic spontaneous urticaria
by: P C Kathuria, et al.
Published: (2022-01-01)

The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
by: Burhan Engin, et al.
Published: (2020-12-01)

Progress in the application of omalizumab in the treatment of chronic inducible urticaria
by: CHEN Ziyan, et al.
Published: (2024-12-01)

Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
by: Anthony F. LaCava, et al.
Published: (2023-08-01)

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
by: Petek Üstün, et al.
Published: (2025-07-01)

Utilidad clínica del omalizumab en urticaria crónica inducible
by: Ricardo Cardona
Published: (2018-06-01)

Cold urticaria with risk of anaphylaxis treated with omalizumab: a case report
by: Tonatiuh Ramses Bedolla-Pulido, et al.
Published: (2021-02-01)

Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years’ Follow-Up: A Case Report
by: Laura Michelina Losappio, et al.
Published: (2020-10-01)

Ciclosporina no Tratamento da Urticária Crónica Espontânea na Era do Omalizumab
by: Bárbara Roque Ferreira, et al.
Published: (2018-05-01)

A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown‐CSU study
by: Murat Türk, et al.
Published: (2024-02-01)

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01)

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments
by: Riccardo Asero, et al.
Published: (2024-11-01)

Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
by: Thomas B. Casale, MD, et al.
Published: (2024-08-01)

Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
by: Shanshan OU, et al.
Published: (2023-04-01)

Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
by: Ragıp Ertaş, et al.
Published: (2016-01-01)

Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients
by: Cristina López, et al.
Published: (2024-08-01)

Acute and Chronic Urticaria: Prevalence, Etiologies, Diagnosis, and Treatment
by: Javad Ghaffari, et al.
Published: (2020-07-01)

Treatment of chronic spontaneous urticaria with a single dose of omalizumab: A study of four cases
by: Radhakrishnan Subramaniyan, et al.
Published: (2016-01-01)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
by: Kiran Godse, et al.
Published: (2016-01-01)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
by: Öner Özdemir
Published: (2023-08-01)

Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
by: Eli Magen
Published: (2019-07-01)

COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
by: Angelo Massimiliano D'Erme, et al.
Published: (2023-08-01)

Potential markers of response to treatment of patients with chronic spontaneous urticaria
by: N. O. Pereverzina, et al.
Published: (2021-06-01)

The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment
by: Gokhan Aytekin, et al.
Published: (2021-09-01)

Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
by: Emek Kocatürk, et al.
Published: (2022-09-01)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
by: Shuang-Lu Liao, et al.
Published: (2021-03-01)

IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
by: Luis Felipe Ensina, et al.
Published: (2025-01-01)

Urticaria crónica idiopática o urticaria espontánea y omalizumab. Revisión del tema a propósito de un caso
by: Giovanni Sedó Mejía, et al.
Published: (2014-05-01)

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
by: Ilya Ivyanskiy, et al.
Published: (2012-01-01)

Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
by: Fikriye Kalkan, et al.
Published: (2025-03-01)

Predictors of response to omalizumab and relapse in chronic spontaneous Urticaria: a narrative review focusing on parameters available in routine clinical practice
by: Laura Mateu-Arrom, et al.
Published: (2025-10-01)

Clinical observation of desloratadine combined with omalizumab in the treatment of chronic spontaneous urticaria
by: Zhiwei SHANG, et al.
Published: (2022-02-01)

Current approaches to the treatment of frequently recurrent urticaria.
by: E. M. Dytyatkovska, et al.
Published: (2020-10-01)

Current approaches to the treatment of frequently recurrent urticaria.
by: E. M. Dytyatkovska, et al.
Published: (2020-10-01)